Syneos Wellbeing Announces Secondary Supplying of Frequent Stock

MORRISVILLE, N.C., June 02, 2021 (Globe NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only absolutely built-in biopharmaceutical methods corporation, today introduced it commenced an underwritten secondary supplying by affiliate marketers of Thomas H. Lee Companions, L.P. and Arrival Intercontinental Company (the “Selling Stockholders”) of an aggregate of 10,851,676 shares of the Company’s typical inventory (the “Offering”) pursuant to the Company’s shelf registration statement submitted with the Securities and Exchange Commission (“SEC”). Syneos Well being is not marketing any shares and will not acquire any proceeds from the sale of the shares by the Advertising Stockholders in the Offering.

In addition, Syneos Wellness entered into an agreement with the Advertising Stockholders to repurchase an combination of 500,000 shares of widespread stock from these kinds of Providing Stockholders in a private transaction, concurrently with the closing of the Supplying, at the rate at which the shares of typical inventory are marketed to the community in the Providing, fewer underwriting bargains and commissions. The closing of the share repurchase is contingent on, and envisioned to happen concurrently with, the closing of the Offering, matter to the fulfillment of other customary disorders. The closing of the Presenting is not contingent on the closing of the share repurchase.

BofA Securities is acting as the sole underwriter of the Featuring.

The underwriter proposes to offer you the shares of widespread inventory from time to time for sale in one particular or extra transactions on the Nasdaq, in the more than-the-counter sector, via negotiated transactions or normally at market price ranges prevailing at the time of sale, at price ranges linked to prevailing marketplace prices or at negotiated rates.

An computerized shelf registration assertion (including a prospectus) relating to the Giving was filed with the SEC on November 27, 2018 and became successful upon submitting. Just before you commit, you should examine the registration statement, prospectus and other paperwork Syneos Well being has created offered with the SEC for details about Syneos Overall health and the Giving. You may well obtain these documents totally free of cost by going to EDGAR on the SEC web-site at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus complement, when accessible, may possibly be acquired from:

BofA Securities, Inc.
NC1-004-03-43
200 North College Street, 3rd ground
Charlotte NC 28255-0001
Attn: Prospectus Section
E-mail: [email protected].

This push release shall not constitute an supply to sell or the solicitation of an provide to buy, nor shall there be any sale of these securities in any point out or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification less than the securities legislation of any these types of state or other jurisdiction.

Forward-Searching Statements

Apart from for historical facts, all of the statements, anticipations, and assumptions contained in this press launch are ahead-hunting statements as that phrase is defined in the Personal Securities Litigation Reform Act of 1995. Genuine effects could differ materially from people explicit or implicit in the ahead-seeking statements. Crucial factors that could result in actual final results to vary materially involve, but are not constrained to: reliance on key personnel principal investigators and people common and worldwide financial, political, and other pitfalls, which include currency and inventory market fluctuations and the uncertain economic setting any failure to realize the predicted added benefits of the acquisitions of SHCR Holdings Company, or Synteract, and Illingworth Investigation Group threats connected to the COVID-19 pandemic the Company’s ability to sufficiently cost its contracts and not overrun expense estimates any adverse consequences from the Company’s purchaser or therapeutic spot concentration the Company’s ability to preserve or generate new enterprise awards the Company’s potential to enhance its market place share, develop its business, and execute its development procedures the Company’s backlog not remaining indicative of long term revenues and its means to understand the expected long run earnings reflected in its backlog fluctuations in the Company’s functioning results and effective money tax level risks associated to the Company’s information methods and cybersecurity adjustments and expenses of compliance with regulations linked to details privacy risks connected to the United Kingdom’s withdrawal from the European Union challenges connected to the Company’s transfer pricing guidelines failure to execute solutions in accordance with contractual specifications, regulatory needs and ethical criteria hazards relating to litigation and governing administration investigations risks linked with the Company’s early section scientific facilities coverage chance challenges of legal responsibility ensuing from hurt to clients achievements of investments in the Company’s customers’ organization or prescription drugs international forex trade amount fluctuations threats connected with acquired organizations, which include the potential to integrate acquired functions, products, and technologies in our business challenges linked to the Company’s cash flow tax cost and tax reform pitfalls relating to the Company’s intellectual assets pitfalls related with the Company’s acquisition technique failure to understand the whole worth of goodwill and intangible belongings restructuring chance potential violations of anti-corruption and anti-bribery regulations challenges similar to the Company’s dependence on 3rd parties downgrades of the Company’s credit rankings level of competition in the biopharmaceutical products and services market modifications in outsourcing trends regulatory hazards developments in the Company’s customers’ firms the Company’s potential to continue to keep tempo with immediate technological improve pitfalls associated to the Company’s indebtedness fluctuations in the Company’s fiscal results and stock price tag and other hazard variables set forth in the Company’s Once-a-year Report on Kind 10-K for the fiscal calendar year ended December 31, 2020, and other SEC filings, copies of which are offered free of charge of demand on the SEC website at www.sec.gov. The Corporation assumes no obligation and does not intend to update these ahead-searching statements, other than as demanded by law.

About Syneos Well being

Syneos Health® (Nasdaq:SYNH) is the only totally built-in biopharmaceutical remedies firm. The Enterprise, which includes a Agreement Exploration Group (CRO) and Agreement Professional Group (CCO), is objective-designed to speed up consumer efficiency to deal with modern-day industry realities. We bring together somewhere around 25,000 medical and commercial minds with the potential to support prospects in much more than 110 nations around the world. Together we share insights, use the hottest systems and use sophisticated small business techniques to velocity our customers’ shipping and delivery of essential therapies to patients.